HeartBeam, Inc. (NASDAQ: BEAT), a medical technology companyfocused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer-to-peer consultations, and on-demand telemedicine visits.
“Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility,” said Robert Eno, CEO of HeartBeam. “Together, we’re enabling patients to have the value of an ECG with timely access to a cardiologist’s interpretation in their pocket and giving physicians a powerful tool to deliver the right care at the right moment.”
The partnership will allow HeartBeam to provide a 24/7 cardiology reader service designed to support patients experiencing cardiac symptoms outside of the traditional healthcare system — providing expert, timely assessment during critical moments.
How It Works
- Patient captures a 30-second recording with HeartBeam’s credit-card-sized, cable-freedevice when they feel arrhythmia symptoms such as palpitations — wherever they are.
- The device’s patented 3D technology captures the heart’s electrical signals in three dimensions and synthesizes them into a 12-lead ECG.
- The synthesized ECG is securely transmitted to the HeartNexus team of board-certifiedcardiologists for immediate review.
- A cardiologist interprets the results for arrhythmia assessment and provides expertfeedback directly to the patient or coordinating clinician.
- Patients will then be able to track their cardiac health through HeartBeam’s secure ecosystem, which will include future enhancements like AI wellness features, community features and wearable integration.
The cardiology reader service is slated for launch following the expected FDA clearance of HeartBeam’s 12-lead ECG synthesis software for assessment of arrhythmias and represents a significant milestone in HeartBeam’s commercialization roadmap. The Company continues to anticipate FDA clearance will occur in Q4 2025.
“This collaboration combines HeartBeam’s innovative ECG technology with HeartNexus’ on-demand cardiology expertise,” said Robert Beto, MD, FACC, CEO of HeartNexus. “It’s a major step toward a more connected, responsive, and patient-centered model of cardiac care.”